These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30946976)

  • 1. Eculizumab hypersensitivity and desensitization in a toddler with atypical hemolytic uremic syndrome.
    Lo R; Alexander S; Moss J; Siddiqi A; Liu A
    J Allergy Clin Immunol Pract; 2019; 7(7):2409-2410. PubMed ID: 30946976
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
    Wijnsma KL; Duineveld C; Wetzels JFM; van de Kar NCAJ
    Pediatr Nephrol; 2019 Nov; 34(11):2261-2277. PubMed ID: 30402748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome.
    Bouwmeester RN; van de Kar NCAJ; Wetzels JFM
    Kidney Int; 2021 Aug; 100(2):265-268. PubMed ID: 33675845
    [No Abstract]   [Full Text] [Related]  

  • 6. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report].
    Reis S; Ramos D; Cordinhã C; Gomes C
    Acta Med Port; 2019 Oct; 32(10):673-675. PubMed ID: 31625881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases.
    Tanaka K; Fujita N; Hibino S
    CEN Case Rep; 2020 Aug; 9(3):247-251. PubMed ID: 32240525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
    Ardissino G; Testa S; Possenti I; Tel F; Paglialonga F; Salardi S; Tedeschi S; Belingheri M; Cugno M
    Am J Kidney Dis; 2014 Oct; 64(4):633-7. PubMed ID: 24656451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.
    Haskin O; Falush Y; Davidovits M
    Pediatr Nephrol; 2019 Dec; 34(12):2601-2604. PubMed ID: 31520126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.
    Socié G; Caby-Tosi MP; Marantz JL; Cole A; Bedrosian CL; Gasteyger C; Mujeebuddin A; Hillmen P; Vande Walle J; Haller H
    Br J Haematol; 2019 Apr; 185(2):297-310. PubMed ID: 30768680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab for atypical hemolytic-uremic syndrome. How long should we maintain it?
    Naranjo Muñoz J; Garcia Garcia-Doncel A; Montero Escobar ME; Villanego Fernandez F; Millán Ortega I; Ceballos Guerrero M
    Nefrologia (Engl Ed); 2019; 39(4):440-442. PubMed ID: 30798995
    [No Abstract]   [Full Text] [Related]  

  • 13. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
    Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.
    Volokhina EB; van de Kar NC; Bergseth G; van der Velden TJ; Westra D; Wetzels JF; van den Heuvel LP; Mollnes TE
    Clin Immunol; 2015 Oct; 160(2):237-43. PubMed ID: 26111482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
    Olson SR; Lu E; Sulpizio E; Shatzel JJ; Rueda JF; DeLoughery TG
    Am J Nephrol; 2018; 48(2):96-107. PubMed ID: 30110670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
    Asif A; Nayer A; Haas CS
    J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab as a treatment for atypical hemolytic syndrome secondary to carfilzomib.
    Moliz C; Gutiérrez E; Cavero T; Redondo B; Praga M
    Nefrologia (Engl Ed); 2019; 39(1):86-88. PubMed ID: 29716757
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.
    Ariceta G
    Pediatr Nephrol; 2019 May; 34(5):943-949. PubMed ID: 30693384
    [No Abstract]   [Full Text] [Related]  

  • 19. Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
    de Ville de Goyet M; Detaille T; Godefroid N
    J Pediatr Hematol Oncol; 2019 Oct; 41(7):e459-e462. PubMed ID: 30933023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.